,i #aadth ,,congress #ast ,session ,h4 ,r4 #ica ,,in ,,the ,,house ,,of ,,representatives ,february #ab1 #bjae ,ms4 ,de,lauro 7for herself1 ,ms4 ,slaughter1 and ,ms4 ,meng7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to provide for approval of certain drugs and biological products indicated for use in a well-defined population of patients in order to address increases in bacterial resistance to drugs and biological products1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,helping ,effective ,antibiotics ,last ,act of #bjae or the ,,heal ,act4 #b4 ,approval of certain drugs for use in a well-defined population of patients 7a7 ,approval of ,certain ,antibacterial ,section #eje of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee7 is amended by adding at the end the following3 7x7 ,approval of certain antibacterial drugs for use in a well-,defined population of patients 7#a7 ,unmet medical need defined ,in this subsection1 the term unmet medical need means that the antibacterial drug involved-- 7,a7 has improved efficacy1 as demonstrated in adequate1 well-controlled studies in humans1 for specific diseases or conditions1 where current therapies have been shown to be less effective2 7,b7 has clinically meaningful decreased harms1 demonstrated in adequate1 well-controlled studies in humans1 for diseases or conditions1 where current therapies have unacceptable adverse effects2 or 7,c7 has improved convenience1 as demonstrated in adequate1 well-controlled studies in humans1 where improved convenience results in improved effectiveness or decreased harms4 7#b7 ,approval ,upon receipt of an application under subsection 7b7 for an antibacterial drug that is intended to treat a serious or life-threatening disease or condition1 irrespective of whether the drug is intended to address an unmet medical need1 the ,secretary-- 7,a7 may approve the drug under subsection 7c7 only for treating a well-defined population of patients1 and based upon the results of clinical trials inclusive of human subjects representative of such well-defined population2 7,b7 in determining whether to grant such approval1 shall rely on superior outcomes over available therapies based on direct measures of patient benefits1 as demonstrated in adequate1 well-controlled studies in the well-defined patient population1 such as-- 7i7 decreased mortality2 7ii7 irreversible morbidity2 or 7iii7 validated surrogate endpoints that reflect mortality or irreversible morbidity2 and 7,c7 shall require the labeling of drugs approved pursuant to this subsection to prominently include in the prescribing information required by section #bja4eg of title #ba1 ,code of ,federal ,regulations 7or any successor regulation7-- 7i7 the population of patients with respect to which the added benefit over available therapies is expected as studied in adequate1 well-controlled studies that form the basis for approval2 and 7ii7 the method for identifying members of that population4 7#c7 ,risk evaluation and mitigation strategy ,the ,secretary-- 7,a7 shall require a risk evaluation and mitigation strategy 7,,rems7 under section #eje-a for each drug approved under this subsection2 and 7,b7 may include in any such strategy additional elements to assure the safe use of the drug under subsections 7e7 and 7f7 of section #eje-a4 7#d7 ,rule of construction ,nothing in this subsection shall be construed to alter the standards of evidence under subsection 7c7 or 7d7 7including the substantial evidence standard in subsection 7d774 ,subsections 7c7 and 7d7 and such standards of evidence apply to the review and approval of drugs under this subsection1 including whether a drug is safe and effective4 ,nothing in this subsection shall be construed to limit the authority of the ,secretary to approve products pursuant to this ,act and the ,public ,health ,service ,act as authorized prior to the date of enactment of this subsection4 7#e7 ,effective immediately ,the ,secretary shall have the authorities vested in the ,secretary by this subsection beginning on the date of enactment of this subsection1 irrespective of when and whether the ,secretary promulgates final regulations to carry out this subsection4 4 7b7 ,licensure of certain biological products ,section #cea7;j7 of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bfb7;j77 is amended-- 7#a7 by striking 7j7 and inserting 7j77#a72 7#b7 by inserting #eje7x71 after #eje7p712 and 7#c7 by adding at the end the following3 7#b7 ,in applying section #eje7x7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act to the licensure of biological products under this section-- 7,a7 references to an antibacterial drug with added benefits over available therapies for a well-defined population that is intended to treat a serious or life-threatening disease or condition shall be construed to refer to biological products with added benefits over available therapies for a well-defined population intended to treat a bacterial infection associated with a serious or life-threatening disease2 and 7,b7 references to an application submitted under section #eje7;b7 of such ,act and to approval of a drug under section #eje7;c7 of such ,act shall be construed to refer to an application submitted under subsection 7a7 of this section and to licensure of a biological product under such subsection 7a71 respectively4 4 7c7 ,monitoring ,title ,,iii of the ,public ,health ,service ,act is amended by inserting after section #cag,t 7#db ,u4,s4,c4 #bdg;b-#bb7 the following3 #cag,u4 ,monitoring of ,antibacterial ,drug ,use1 ,patient ,outcomes1 and ,resistance 7a7 ,monitoring ,the ,secretary1 acting through the ,director of the ,centers for ,disease ,control and ,prevention1 shall use the ,national ,healthcare ,safety ,network or another appropriate monitoring system to monitor-- 7#a7 changes in patient outcomes such as mortality and irreversible morbidity causally related to antibacterial resistance2 and 7#b7 changes in bacterial resistance to drugs in relation to patient outcomes4 7b7 ,public availability of data ,the ,secretary1 acting through the ,director of the ,centers for ,disease ,control and ,prevention1 shall make the data derived from monitoring under this section publicly available for the purposes of-- 7#a7 improving the monitoring of important trends in patient outcomes in relation to antibacterial resistance2 and 7#b7 ensuring appropriate stewardship of antibacterial drugs1 including those receiving approval or licensure for a well-defined population pursuant to section #eje7x7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act4 4 #c4 ,susceptibility test interpretive criteria for microbial organisms 7a7 ,in general ,section #eaa of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;a7 is amended to read as follows3 #eaa4 ,susceptibility test interpretive criteria for microbial organisms 7a7 ,in general ,the ,secretary shall-- 7#a7 identify upon approval or licensing of antibacterial drugs 7including biological products intended to treat a bacterial infection and other types of antimicrobial drugs1 as deemed appropriate by the ,secretary71 including qualified infectious disease products1 susceptibility test interpretive criteria for such drugs based upon patient outcomes of mortality and morbidity from adequate and well-controlled studies and such other confirmatory evidence as the ,secretary deems necessary2 and 7#b7 update1 consistent with subsection 7b71 such criteria as needed based upon scientific evidence of changes in patient outcomes4 7b7 ,responding to ,changes in ,patient ,outcomes ,to ,evaluate ,susceptibility ,test ,interpretive ,criteria 7#a7 ,in general ,as needed based on evidence related to changes in patient outcomes1 the ,secretary shall-- 7,a7 evaluate any new scientific studies on changes in patient outcomes in relation to susceptibility test interpretive criteria2 and 7,b7 publish on the public ,website of the ,food and ,drug ,administration a notice-- 7i7 presenting suggested new or updated interpretive criteria2 and 7ii7 if needed1 hold a public advisory committee to discuss scientific evidence related to changes in interpretative criteria4 7#b7 ,annual compilation of notices ,each year1 the ,secretary shall compile the notices published under paragraph 7#a77;,b7 noting any changes from prior notices and publish such compilation in the ,federal ,register4 7c7 ,definition ,in this section1 the term susceptibility test interpretive criteria means one or more specific values which characterize patient outcomes in relation to the degree to which bacteria or other microbes are more resistant to treatment as measured by patient outcomes4 4 7b7 ,conforming amendment ,section #aaaa of the ,food and ,drug ,administration ,amendments ,act of #bjjg 7#db ,u4,s4,c4 #bdg;d-#e;a2 relating to identification of clinically susceptible concentrations of antimicrobials7 is repealed4 7c7 ,report to congress ,not later than one year after the date of enactment of this ,act1 the ,secretary of ,health and ,human ,services shall submit to the ,committee on ,energy and ,commerce of the ,house of ,representatives and the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate a report on the progress made in implementing section #eaa of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cfj;a71 as amended by this section4 #d4 ,requiring demonstration of superior outcomes for qualified infectious disease products ,to receive an extended exclusivity period ,section #eje;,e7g7 of the ,federal ,food1 ,drug1 and ,cosmetic ,act 7#ba ,u4,s4,c4 #cee;f7g77 is amended by striking means an antibacterial or antifungal drug for human use intended to treat and inserting means an antibacterial or antifungal drug for human use that is demonstrated to produce superior outcomes over available therapies1 based on direct measures of patient benefits in clinical trials1 and that is intended to treat4 #e4 ,guidance on target product profiles ,not later than #ah months after the date of enactment of this ,act1 the ,commissioner of ,food and ,drugs1 in consultation with the ,administrator of the ,centers for ,medicare ,medicaid ,services1 the ,director of the ,indian ,health ,service1 the ,secretary of ,defense1 and the ,secretary of ,veterans ,affairs1 shall issue guidance on the development of target product profiles for novel antibacterial drugs focused on public health priorities4